Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Cells for Spinal Cord Injury
NCT01833975Phase 2
Key facts
- Status
- Unknown
- Start
- Sep 2014
- Primary completion
- Sep 2016
- Countries
- 1
- Sponsor
- Chaitanya Hospital
- Modality
- Stem Cell Therapies
- Conditions
- spinal cord injury (SCI)
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in spinal cord injury (SCI), sponsored by Chaitanya Hospital. Primary endpoint: Improvement in overall sensory for motor control using Frankel score at 6 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
stem cell [ MNCs ]
Intrathecal transplantation of autologous bone marrow-derived mononuclear cells
03
Who it enrols
Patients with traumatic spinal cord injury (complete or partial) below C4 level, aged 18-55 years.
04
Endpoints
Primary
Improvement in overall sensory for motor control using Frankel score
Secondary
Improvement in pain sensation
Significant changes in Muscle Tones
Improvement in sensory and motor dysfunction using ASIA Scale
Beyond the preview
Go deeper on NCT01833975.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01833975.